Unbiased metabolic profiling predicts sensitivity of high MYC-expressing atypical teratoid/ rhabdoid tumors to glutamine inhibition with 6-diazo-5-oxo-L-norleucine

Sabrina Z. Wang, Brad Poore, Jesse Alt, Antoinette Price, Sariah J. Allen, Allison R. Hanaford, Harpreet Kaur, Brent A. Orr, Barbara S. Slusher, Charles G. Eberhart, Eric H. Raabe, Jeffrey A. Rubens

Research output: Contribution to journalArticle

Abstract

Purpose: Atypical teratoid/rhabdoid tumors (AT/RT) are aggressive infantile brain tumors with poor survival. Recent advancements have highlighted significant molecular heterogeneity in AT/RT with an aggressive subgroup featuring overexpression of the MYC proto-oncogene. We perform the first comprehensive metabolic profiling of patient-derived AT/RT cell lines to identify therapeutic susceptibilities in high MYC-expressing AT/RT. Experimental Design: Metabolites were extracted from AT/RT cell lines and separated in ultra-high performance liquid chromatography mass spectrometry. Glutamine metabolic inhibition with 6-diazo-5-oxo-L-norleucine (DON) was tested with growth and cell death assays and survival studies in orthotopic mouse models of AT/RT. Metabolic flux analysis was completed to identify combination therapies to act synergistically to improve survival in high MYC AT/RT. Results: Unbiased metabolic profiling of AT/RT cell models identified a unique dependence of high MYC AT/RT on glutamine for survival. The glutamine analogue, DON, selectively targeted high MYC cell lines, slowing cell growth, inducing apoptosis, and extending survival in orthotopic mouse models of AT/RT. Metabolic flux experiments with isotopically labeled glutamine revealed DON inhibition of glutathione (GSH) synthesis. DON combined with carboplatin further slowed cell growth, induced apoptosis, and extended survival in orthotopic mouse models of high MYC AT/RT. Conclusions: Unbiased metabolic profiling of AT/RT identified susceptibility of high MYC AT/RT to glutamine metabolic inhibition with DON therapy. DON inhibited glutamine-dependent synthesis of GSH and synergized with carboplatin to extend survival in high MYC AT/RT. These findings can rapidly translate into new clinical trials to improve survival in high MYC AT/RT.

Original languageEnglish (US)
Pages (from-to)5925-5936
Number of pages12
JournalClinical Cancer Research
Volume25
Issue number19
DOIs
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Unbiased metabolic profiling predicts sensitivity of high MYC-expressing atypical teratoid/ rhabdoid tumors to glutamine inhibition with 6-diazo-5-oxo-L-norleucine'. Together they form a unique fingerprint.

  • Cite this